What Does EUSA Pharma Do?

Total employees102
HeadquartersHemel Hempstead
FoundedN/A

EUSA Pharma is a global biopharmaceutical company with a focus on oncology and rare diseases. The company is committed to developing and commercializing innovative treatments that can make a real difference to patients' lives. EUSA Pharma has a portfolio of specialized medicines and a pipeline of promising therapies, driven by a patient-centric approach. They strive to address unmet medical needs and improve outcomes for individuals affected by complex conditions worldwide. Since its acquisition in 2022, EUSA Pharma is part of the Recordati Group, enhancing its capabilities and global reach.

Where Is EUSA Pharma's Headquarters?

HQ Function

The UK headquarters serves as the central hub for EUSA Pharma's global operations, including strategic planning, corporate governance, research and development oversight, and international commercial coordination.

Notable Features:

Located within Breakspear Park, a modern and well-equipped business park offering a professional environment with good amenities and transport links to London and international airports.

Work Culture:

The work culture at EUSA Pharma's headquarters likely emphasizes collaboration, innovation, and a strong patient-first mindset, reflecting its mission in the biopharmaceutical sector. Employees are driven by the impact of their work on patients with serious diseases.

HQ Significance:

The headquarters' location in the UK is significant for its proximity to leading research institutions, regulatory bodies like the MHRA, and a skilled talent pool in the pharmaceutical industry. It facilitates collaboration and strategic partnerships within Europe and globally.

Values Reflected in HQ: The choice of a modern, well-connected, and professional business park reflects EUSA Pharma's commitment to efficiency, innovation, and global connectivity in its pursuit of advancing healthcare solutions.

Location:

EUSA Pharma maintains a significant global presence with direct commercial operations in the United States and key European countries. Beyond these regions, the company extends its reach through a network of trusted distribution partners, making its specialized oncology and rare disease therapies available to patients in numerous international markets. Global functions supported include clinical development, regulatory affairs, medical affairs, supply chain management, and commercialization.

Street Address:

Breakspear Park, Breakspear Way

City:

Hemel Hempstead

State/Province:

Hertfordshire

Country:

United Kingdom

Where Else Does EUSA Pharma Operate Around the World?

Langhorne, Pennsylvania, USA

Address: 111 North Congressional Lane, Suite 200, Langhorne, PA 19047, USA

To drive the commercialization and availability of EUSA Pharma's specialized treatments to patients in the U.S., engaging with healthcare professionals, regulatory authorities (FDA), and patient advocacy groups.

Lyon, France

Address: Parc des Gaulnes, 355 Allée Jacques Monod, 69150 Décines-Charpieu, France

To manage and expand EUSA Pharma's presence in key European markets, ensuring patient access to its therapies and coordinating with national health authorities.

Buying Intent Signals for EUSA Pharma

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading EUSA Pharma? Meet the Executive Team

As of April 2025, EUSA Pharma' leadership includes:

Darrel P. Cohen, M.D., Ph.D. - Chief Executive Officer
Bryan Morton - Founder & Chairman
Lee Morley - Chief Operating Officer
John Lemkey - Chief Financial Officer
Ruth Thieroff-Ekerdt, MD - Chief Medical Officer and Head of R&D

Who's Investing in EUSA Pharma?

EUSA Pharma has been backed by several prominent investors over the years, including:

Recordati S.p.A. (Acquirer/Parent Company)

What Leadership Changes Has EUSA Pharma Seen Recently?

Hire1
Exits1

Over the past year or so, EUSA Pharma experienced a significant leadership transition with the appointment of a new CEO. Other team adjustments may have occurred as part of strategic alignments following its acquisition by Recordati.

Departures

Dr. Carsten Thiel, Dr. Carsten Thiel departed from his role as CEO of EUSA Pharma.

New Appointments:

Dr. Darrel P. Cohen, Dr. Darrel P. Cohen was appointed as the new Chief Executive Officer, tasked with leading EUSA Pharma's next phase of growth.

What Technology (Tech Stack) Is Used byEUSA Pharma?

Discover the tools EUSA Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

EUSA Pharma Email Formats and Examples

EUSA Pharma likely uses standard professional email formats. Common patterns in the pharmaceutical industry include [first].[last]@domain.com or [firstinitial][last]@domain.com.

[first].[last]@eusapharma.com

Format

jane.doe@eusapharma.com

Example

80%

Success rate

What's the Latest News About EUSA Pharma?

Recordati Press ReleaseMay 24, 2022

EUSA Pharma Acquired by Recordati

Recordati S.p.A. announced the completion of its acquisition of EUSA Pharma, a global specialty pharmaceutical company focused on rare diseases. This acquisition significantly strengthens Recordati's portfolio and presence in the rare disease market....more

EUSA Pharma Press ReleaseOctober 5, 2022

EUSA Pharma Appoints Darrel P. Cohen, M.D., Ph.D., as Chief Executive Officer

EUSA Pharma announced the appointment of Darrel P. Cohen, M.D., Ph.D., as its new Chief Executive Officer. Dr. Cohen brings a wealth of experience in the biopharmaceutical industry, particularly in oncology and rare diseases, to lead EUSA Pharma into its next chapter of growth....more

Recordati Full Year 2023 ResultsFebruary 27, 2024

EUSA Pharma Contributes to Recordati's Strong Performance in Rare Diseases

Recordati's full-year 2023 financial results highlighted the positive contribution of EUSA Pharma's portfolio to its Rare Diseases segment. Products like QARZIBA® (dinutuximab beta) and Sylvant® (siltuximab) were noted for their performance, underscoring EUSA's strategic importance within the Recordati group....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including EUSA Pharma, are just a search away.